Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors

Pediatric Infectious Disease Journal

Volumn 28, Issue 7, 2009, Pages 619-625

  Andiman, Warren A ^a   Chernoff, Miriam C ^b   Mitchell, Charles ^c   Purswani, Murli ^d   Oleske, James ^e   Williams, Paige L ^b   Spiegel, Hans ^f   Gona, Phil ^g   Seage, George R ^h  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g Boston University   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Complications of antiretroviral therapy; Nephrotoxic medications; Pediatric HIV AIDS; Renal disease

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; MALE; NEWBORN; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; AIDS-ASSOCIATED NEPHROPATHY; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 74349088256     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31819ca49a     Document Type: Review

References (39)

1. Gona P, Van Dyke RB, Williams PL, et al. Incidence ofopportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296:292-300. (Pubitemid 44079313)
2. Nachman SA, Van Dyke RB, Gona P, et al. Incidence of non-infectious complications in perinatally HIV-infected children and adolescents in the HAART era. In: 42nd Annual Meeting of the Infectious Diseases Society of America; 2004; Boston, MA. Abstract 951.
3. Chaparro AI, Mitchell CD, Abitbol CL, et al. Proteinuria in children infected with the human immunodeficiency virus. J Pediatr. 2008;152: 844-849.
4. Ray PE, Rakusan T, Loechelt BJ, et al. Human immunodeficiency virus (HIV)-associated nephropathy in children from the Washington, DC area: 12 years' experience. Semin Nephrol. 1998;18:396-405. (Pubitemid 28340463)
5. Strauss J, Abitbol C, Zilleruelo G, et al. Renal disease in children with the acquired immunodeficiency syndrome. N Engl J Med. 1989;321:625-630. (Pubitemid 19221305)
6. Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molec-ular pathologic correlations, and genetic investigations. Ann Intern Med. 2003;139:214-226. (Pubitemid 38124604)
7. Gupta SK, Mamlin BW, Johnson CS, et al. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol. 2004;61:1-6. (Pubitemid 38100837)
8. Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis. 2001;33:115-119. (Pubitemid 32554512)
9. Chodakewitz J, Deutsch P, Leavitt R, et al. Preliminary evaluation of the long term safety and antiviral activity exerted by CRIXIVAN (MK-639), an oral HIV protease inhibitor. In: 5th European Conference Abstracts: Clin-ical and Treatment of HIV; 1995; Copenhagen, Denmark.
10. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324:342-344. (Pubitemid 36109329)
11. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am JKidney Dis. 2002;40: 1331-1333. (Pubitemid 35403147)
12. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage ther-apy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711-e718. (Pubitemid 46089998)
13. Papaleo A, Warszawski J, Salomon R, et al. Increased beta-2 microglobu-linuria in human immunodeficiency virus-1-infected children and adoles-cents treated with tenofovir. Pediatr Infect Dis J. 2007;26:949-951. (Pubitemid 47494169)
14. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside re-verse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102-108. (Pubitemid 351263473)
15. Olyaei AJ, de Mattos AM, Bennett WM. Renal toxicity ofprotease inhibi-tors. Curr Opin Nephrol Hypertens. 2000;9:473-476.
16. Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol. 2006;21:1034-1036. (Pubitemid 43885106)
17. Blood Chemistries/Body Fluids. In: Siberry GK, Iannone R, eds. The Harriet Lane Handbook: AManualfor Pediatric House Officers. 15 ed. St. Louis, France: Mosby Inc.; 2000: 1042.
18. Schwartz GJ, Haycock GB, Edelmann CM Jr, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259-263.
19. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management ofchronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585. (Pubitemid 40720806)
20. Cox DR. Regression Models and Life-Tables. J R Stat Soc Ser B (Meth-odological). 1972;34:187-220.
21. Collett D. Modelling Survival Data in Medical Research. London: Chap-man and Hall; 1994.
22. Yeh KC, Kwan KC. A comparison ofnumerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm. 1978;6:79-98. (Pubitemid 8314204)
23. Saulsbury F. Resolution oforgan-specific complications of human immu-nodeficiency virus infection in children with use of highly active antiret-roviral therapy. Clin Infect Dis. 2001;32:464-468. (Pubitemid 32173634)
24. Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-associ-ated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci. 2002;323:102-106. (Pubitemid 34651563)
25. Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22:481-487. (Pubitemid 351317289)
26. Post FA, Campbell LJ, Hamzah L, et al. Predictors of renal outcome in HIV-associatednephropathy. Clin Infect Dis. 2008;46:1282-1289.
27. Wali RK, Drachenberg CI, Papadimitriou JC, et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet. 1998;352:783-784. (Pubitemid 28404562)
28. Freedman BI, Soucie JM, Stone SM, et al. Familial clustering ofend-stage renal disease in blacks with HIV-associated nephropathy. Am JKidney Dis. 1999;34:254-258. (Pubitemid 29362089)
29. Kopp JB, Winkler C. HIV-associated nephropathy in African Americans. Kidney Int Suppl. 2003;S43-S49. (Pubitemid 36126842)
30. Martins D, Tareen N, Norris KC. The epidemiology of end-stage renal disease among African Americans. Am J Med Sci. 2002;323:65-71. (Pubitemid 34651556)
31. Lucas GM, Lau B, Atta MG, et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in hiv-infected individuals: a tale of two races. J Infect Dis. 2008;197:1548-1557. (Pubitemid 351706485)
32. Casanova S, Mazzucco G, Barbiano di Belgiojoso G, et al. Pattern of glomerular involvement in human immunodeficiency virus-infected pa-tients: an Italian study. Am J Kidney Dis. 1995;26:446-453.
33. Connolly JO, Weston CE, Hendry BM. HIV-associated renal disease in Londonhospitals. QJM. 1995;88:627-634.
34. Saydah S, Eberhardt M, Rios-Burrows N, et al. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. Morb Mortal Wkly Rep. 2007:161-165.
35. Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. JAm Soc Nephrol. 2000;11:2079-2087.
36. D'Agati V, Appel GB. HIV infection and the kidney. JAm Soc Nephrol. 1997;8:138-152. (Pubitemid 27496526)
37. Ross MJ, Bruggeman LA, Wilson PD, et al. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. JAm Soc Nephrol. 2001;12:2645-2651. (Pubitemid 33115411)
38. Estrella M, Fine DM, Gallant JE, et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis. 2006;43:377-380. (Pubitemid 44078912)
39. Izzedine H, Wirden M, Launay-Vacher V. Viral load and HIV-associated nephropathy. NEngl J Med. 2005;353:1072-1074.